# Johnson & Johnson (JNJ)

Source: https://www.quantisnow.com/company/JNJ
Generated: 2026-11-22T19:26:00.324Z

- Ticker: JNJ
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000200406
- Website: jnj.com

## About

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

## Latest JNJ news and filings

- 2026-11-20 13:00 UTC [Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness](https://www.quantisnow.com/insight/johnson-johnson-data-in-psoriatic-arthritis-psa-shows-tremfya-guselkumab-6801629)
- 2026-11-19 13:51 UTC [Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System](https://www.quantisnow.com/insight/johnson-johnson-announces-first-commercial-installation-of-the-ottava-robotic-6800133)
- 2026-11-19 13:01 UTC [Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication](https://www.quantisnow.com/insight/johnson-johnson-seeks-us-fda-approval-for-caplyta-in-bipolar-6800019)
- 2026-11-16 13:00 UTC [Mergers & Acquisitions] [Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology](https://www.quantisnow.com/insight/johnson-johnson-to-acquire-ollin-biosciences-and-late-stage-bispecific-antibody-6792375)
- 2026-11-13 21:54 UTC [SEC Form 4] [EVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-legal-officer-forminard-elizabeth-exercised-13072-shares-at-6791241)
- 2026-11-13 13:27 UTC [FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH](https://www.quantisnow.com/insight/fda-approval-for-lazcluze-issued-to-janssen-biotech-6789509)
- 2026-11-10 13:00 UTC [Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study](https://www.quantisnow.com/insight/johnson-johnson-announces-caplyta-lumateperone-shows-significant-and-rapid-improvement-6783022)
- 2026-11-09 16:36 UTC [Mergers & Acquisitions] [Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment](https://www.quantisnow.com/insight/raised-outlooks-and-a-cancer-approval-arrive-in-the-middle-6780797)
- 2026-11-07 15:03 UTC [Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide](https://www.quantisnow.com/insight/johnson-johnson-announces-icotyde-icotrokinra-delivers-significant-improvement-in-psoriatic-6779782)
- 2026-11-07 15:03 UTC [Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients](https://www.quantisnow.com/insight/johnson-johnson-announces-new-phase-2-nipocalimab-study-data-in-6779781)
- 2026-11-06 16:12 UTC [FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH](https://www.quantisnow.com/insight/fda-approval-for-rybrevant-faspro-issued-to-janssen-biotech-6778415)
- 2026-11-06 02:03 UTC [Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer](https://www.quantisnow.com/insight/johnson-johnson-announces-us-fda-approval-of-rybrevant-faspro-amivantamab-6777629)
- 2026-11-01 13:00 UTC [Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results](https://www.quantisnow.com/insight/data-show-positive-survival-and-patient-outcomes-with-best-practice-impella-6765778)
- 2026-10-27 11:30 UTC [Johnson & Johnson to Host Enterprise Business Review](https://www.quantisnow.com/insight/johnson-johnson-to-host-enterprise-business-review-6758483)
- 2026-10-26 20:38 UTC [SEC Form 13F-HR filed by Johnson & Johnson](https://www.quantisnow.com/insight/sec-form-13f-hr-filed-by-johnson-johnson-6757822)
- 2026-10-25 13:45 UTC [RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer](https://www.quantisnow.com/insight/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-6756746)
- 2026-10-25 07:30 UTC [Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule](https://www.quantisnow.com/insight/johnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-6756737)
- 2026-10-24 12:54 UTC [Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer](https://www.quantisnow.com/insight/johnson-johnson-announces-erleada-apalutamide-treatment-before-and-after-surgery-6756728)
- 2026-10-22 11:45 UTC [Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026](https://www.quantisnow.com/insight/johnson-johnson-reports-first-real-world-varipulse-pro-platform-data-and-6754393)
- 2026-10-21 20:18 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Johnson & Johnson](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-johnson-johnson-6753650)
- 2026-10-21 10:31 UTC [Analyst Downgrade] [Johnson & Johnson downgraded by Erste Group](https://www.quantisnow.com/insight/johnson-johnson-downgraded-by-erste-group-6752758)
- 2026-10-19 12:00 UTC [Johnson & Johnson   announces   new data   showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula   remission through 48 weeks in Crohn's disease with perianal fistula](https://www.quantisnow.com/insight/johnson-johnson-announces-new-data-showing-tremfya-guselkumab-is-the-6750112)
- 2026-10-13 12:12 UTC [SEC Form 8-K] [SEC Form 8-K filed by Johnson & Johnson](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-johnson-johnson-6744305)
- 2026-10-13 10:25 UTC [Dividends] [Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026](https://www.quantisnow.com/insight/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2026-6743966)
- 2026-10-13 10:20 UTC [Earnings Date] [Johnson & Johnson reports Q3 2026 results, raises 2026 guidance](https://www.quantisnow.com/insight/johnson-johnson-reports-q3-2026-results-raises-2026-guidance-6743952)
- 2026-10-12 20:05 UTC [TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease](https://www.quantisnow.com/insight/tremfya-guselkumab-demonstrated-sustained-clinical-and-endoscopic-remission-through-3-6743739)
- 2026-10-12 20:05 UTC [New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups](https://www.quantisnow.com/insight/new-tremfya-guselkumab-study-shows-consistent-perianal-fistula-remission-across-6743737)
- 2026-10-12 11:29 UTC [Earnings Date] [After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports](https://www.quantisnow.com/insight/after-a-record-setting-week-wall-street-turns-to-inflation-data-6743445)
- 2026-10-09 11:00 UTC [New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis](https://www.quantisnow.com/insight/new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-6742341)
- 2026-10-07 13:59 UTC [2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope](https://www.quantisnow.com/insight/2026-takes-a-promising-turn-in-the-fight-against-cancer-6740027)
- 2026-10-02 10:00 UTC [Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy](https://www.quantisnow.com/insight/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-6733315)
- 2026-10-01 11:45 UTC [New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause](https://www.quantisnow.com/insight/new-global-survey-by-johnson-johnson-finds-most-women-dont-6731416)
- 2026-09-29 12:03 UTC [Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)](https://www.quantisnow.com/insight/johnson-johnson-presents-new-data-reinforcing-sustained-disease-control-and-6728479)
- 2026-09-25 11:30 UTC [Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study](https://www.quantisnow.com/insight/johnson-johnson-announces-tremfya-guselkumab-is-the-first-and-only-6725995)
- 2026-09-25 11:00 UTC [Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma](https://www.quantisnow.com/insight/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-five-year-treatment-free-remissions-6725979)
- 2026-09-23 13:46 UTC [New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma](https://www.quantisnow.com/insight/new-model-based-analysis-further-supports-the-potential-of-tecvayli-teclistamab-cqyv-6723934)
- 2026-09-22 12:00 UTC [DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026](https://www.quantisnow.com/insight/depuy-synthes-showcases-next-generation-trauma-innovations-at-ota-2026-6722371)
- 2026-09-21 12:00 UTC [CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study](https://www.quantisnow.com/insight/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-6721257)
- 2026-09-15 03:00 UTC [RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026](https://www.quantisnow.com/insight/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-lazcluze-lazertinib-with-prophylactic-6715176)
- 2026-09-14 01:45 UTC [Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer](https://www.quantisnow.com/insight/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-6713496)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/JNJ
- Earnings history: https://www.quantisnow.com/earnings/JNJ
- Dividend history: https://www.quantisnow.com/dividends/JNJ
- Insider transactions: https://www.quantisnow.com/insiders/JNJ
- Options chain: https://www.quantisnow.com/options/JNJ
- SEC 8-K filings only: https://www.quantisnow.com/company/JNJ/8-k
- RSS and alerts for JNJ: https://www.quantisnow.com/docs/rss-feeds.md
